Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced today that it has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. The transaction is subject to regulatory approval and is expected to close in December 2012.
|
Thu, 11/29/2012
|
||
|
Tue, 10/30/2012
Healthpoint Biotherapeutics today announced the introduction of a 5 cm x 7 cm size of OASIS® Ultra Tri-Layer Matrix, a naturally-derived extracellular matrix (ECM) material formed from three layers of porcine small intestinal submucosa (SIS). |
||
|
Mon, 09/17/2012
Healthpoint Biotherapeutics today announced it has been named a 2012 Bronze STEVIE® Award Winner for the Video-Training category in The 10th Annual American Business Awards. The award was granted for the SENSES Program, a training DVD with accompanying poster, training card and recognition pins, developed to educate caregivers in the long-term care setting on how to recognize the signs of potential pressure ulcer development. |
||
Tue, 09/11/2012
Healthpoint Biotherapeutics today announced the initiation of a Phase lll clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control plus compression therapy over the 12-week treatment period. |
||
|
Mon, 08/13/2012
The Wound Institute today announced it has been named a 2012 Gold Award Winner in the 14th annual Web Health Awards[SM] for its online Medical Education platform developed for healthcare professionals. Additionally, The Wound Institute Patient Portal, which provides educational resources designed for patients and caregivers, received a Merit Award. |
